Aspira Pathlab & Diagnostics Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakhs)
Aspira Pathlab & Diagnostics Ltd · Outcome · 06 Nov 2026, 9:52 pm
Aspira Pathlab & Diagnostics Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakhs) ■ Revenue: 626 (-22.6% YoY | +1.5% QoQ) ■ EBITDA: -67.5 (Profit to Loss YoY | Profit to Loss QoQ) ■ EBITDA Margin (%): -10.8 (Profit to Loss YoY | Profit to Loss QoQ) ■ PAT: -116 (Profit to Loss YoY | -2975.6% QoQ) ■ EPS (INR): -1.13 (Profit to Loss YoY | -2725.0% QoQ)
Original exchange filing (PDF)
More announcements from Aspira Pathlab & Diagnostics Ltd
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jay Arvind Bhanushali · 14 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jay Arvind Bhanushali · 14 Nov 2026
- Enclosed herewith Financial Result for the Half Year ended 30th September 2026 · 06 Nov 2026
- Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2026 ,inter alia, to consider and approve Un-audited Financial .... · 06 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jay Arvind Bhanushali · 01 Oct 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jay Arvind Bhanushali · 28 Sept 2026
- Disclosure of Voting Results of 53rd Annual General Meeting along with the Scrutinizer Report · 26 Sept 2026
- Please find attached summary of proceeding /outcome of the 53rd Annual General Meeting of the Company held on Friday,25th September,2026 · 26 Sept 2026
